References
- Brown R. T., Braden N. J. Hallucinogens. Ped. Clin. N. Am. 1987; 34: 341
- Nelson C. C., Foltz R. L. Chromatographic and mass spectrometric methods for determination of lysergic acid diethylamide (LSD) and metabolites in body fluids. J. Chromatogr. 1992; 580: 97
- Abbas A. K., Urioste S., Collins T. L., Boom W. H. Heterogeneity of helper/inducer T lymphocytes: IV Stimulation of resting and activated B cells by Th1 and Th2 clones. J. Immunol. 1990; 144: 2031
- Gillis S., Ferm M. M., Ou W., Smith K. A. T-cell growth factor: Parameters of production and a quantitative microassay for activity. J. Immunol. 1978; 120: 2027
- Hu-Li J., Ohara J., Watson C., Tsang W., Paul W. E. Derivation of a T-cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and an IL-2 hyporesponsive mutant of that line (CT.4S). J. Immunol. 1989; 142: 800
- House R. V., Lauer L. D., Murray M. J., Dean J. H. Suppression of T-helper cell function in mice following exposure to the carcinogen 7,12-dimethylbenz[a]anthracene and its restoration by interleukin-2. Intl. J. Immunopharmacol. 1987; 9: 89
- Talmadge J. E. Immunoregulation and immunostimulation of murine lymphocytes by recombinant human interleukin-2. J. Biol. Res. Modif. 1985; 4: 18
- Van Snick J., Caypahs S., Vink A., et al. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybriomas. Proc. Natl. Acad. Sci. 1986; 83: 9679
- Carroll M. E. POP and hallucinogens. Advances in Substance Abuse, M. K. Erickson, M. A. Javors, W. W. Morgan. Haworth Press, Inc., Binghamton, NY 1990; Vol 9: 167
- Kulig K. LSD. Emerg. Med. Clin. N. Am. 1990; 8: 551
- Chiang W., Goldfrank L. The medical complications of drug abuse. Med. J. Australia 1990; 152: 83
- Pillai R. M., Watson R. R. In vitro immunotoxicology and immunopharmacology: Studies on drugs of abuse. Toxicol. Lett. 1990; 53: 269
- Mosmann T. R., Schumacher J. H., Street N. F., Budd R., O'Garra A., Fong T. A.T., Bond M. W., Moore K. W.M., Sher A., Fiorentino D. F. Diversity of cytokine synthesis and function of mouse CD4+ T cell. Immunol. Rev. 1991; 123: 209
- Berke G. The cytolytic T lymphocyte and its mode of action. Immunol. Lett. 1989; 20: 169
- Taylor M. K., Cohen J. J. Cell-mediated cytotoxicity. Curr. Opin. Immunol. 1992; 4: 338
- Skinner M. A., Finberg R. W., Ertl H. C.J. Regulation of cytotoxic lymphocyte precursors. II. The effect of interleukin-2 and interferon-γ on the apparent specificity of effector cells. Cell. Immunol. 1986; 100: 239
- Trenn G., Takayama H., Hu-Li J, Paul W. E., Sitkovsky M. V. B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes. J. Immunol. 1988; 140: 1101
- House R. V., Pallardy M. J., Cornacoff J. B., Thurmond L. M., Dean J. H. Suppression of cytolytic function in murine lymphocytes exposed to 1,4-bis[(2-aminoethyl)amino]-5,8-dihydroxy-9,10-anthracenedione dihydrochloride (AEAD): Inhibition of proliferation by cytotoxic T-lymphocyte precursors. Intl. J. Immunopharmacol. 1989; 11: 301
- Oldham R. K. Natural killer cells: History, relevance. and clinical applications. Nat. Immun. Cell Growth Regul. 1990; 9: 297
- Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin. Immunol. Immunopathol. 1992; 62: 860
- Upshall D. G., Wailling D. G. The determination of LSD in human plasma following oral administration. Clin. Chim. Acta 1972; 36: 67